Ipsen Shelves Cabometyx in Prostate Cancer After Phase III Miss
Monday, 16 September 2024, 06:13
Overview of Cabometyx and Prostate Cancer
Cabometyx, a medication used in prostate cancer, has recently been affected by clinical trial results. Following its Phase III miss, Ipsen has decided to shelve the current combination therapy. This decision could influence treatment options for patients.
Impacts on Future Submissions
Despite Ipsen's pullback, Exelixis, the US rights holder, plans to continue with its submission to the FDA. This demonstrates ongoing commitment to advance prostate cancer treatments.
- Impact on clinical trials
- Direction of treatment development
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.